© Valneva SE

French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.

© pixabay/ Jukka Niittymaa

The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.

Active centre of the IMP dehydrogenase. © University of Luebeck/DESY, Lars Redecke

Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.

Aedes mosquito. © Imperial College London

Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.

© Mutabilis SA

The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.

Arek Socha/Pixabay.com

Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing

© iOnctura SA

Merck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.

© BMEL/photothek.net

Ministers from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.

HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic.

© Nestlé Institute für Packaging Sciences

Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives.